Core Viewpoint - Haofan Bio (301393.SZ) announced changes in the use of raised funds and project completion timelines due to external policy changes and operational needs [1] Group 1: Fund Usage Changes - The project "Suzhou Haofan Bio Co., Ltd. 100kg/year peptide and protein reagent R&D and production and headquarters construction project (Phase I)" has reached a usable state, and the remaining funds will be used to supplement working capital [1] - The company plans to change the use of a total of 49,696.68 million yuan of raised funds from the "Anhui Haofan peptide reagent and pharmaceutical intermediates construction project" and "peptide and protein reagent R&D platform construction project" to the "Huaian Haofan production base construction project" [1] - The remaining funds after the changes will be used to supplement working capital, with the net amount being cash management income minus handling fees [1] Group 2: Project Completion and Timeline Adjustments - The "Anhui Haofan peptide reagent and pharmaceutical intermediates construction project" and "peptide and protein reagent R&D platform construction project" are proposed to be completed [1] - The timeline for the "Huaian Haofan production base construction project" is extended to December 2028 to ensure safe, rapid, and orderly capacity construction [1]

Core Points - Haofan Bio (301393.SZ) announced the approval of changes in the use of raised funds and the completion of certain fundraising projects during its board and supervisory meetings [1] Group 1: Fund Utilization Changes - The project "Suzhou Haofan Bio Co., Ltd. 100kg/year peptide and protein reagent R&D and production and headquarters construction project (Phase I)" has reached a state of intended use, and the remaining funds will be used to supplement working capital [1] - Due to external policy changes and the current operational needs, the company plans to change the use of a total of 49,696.68 million yuan of raised funds from the "Anhui Haofan peptide reagent and pharmaceutical intermediates construction project" and "peptide and protein reagent R&D platform construction project" to the "Huaian Haofan production base construction project" [1] - The "Anhui Haofan peptide reagent and pharmaceutical intermediates construction project" and "peptide and protein reagent R&D platform construction project" are proposed to be completed, with the remaining funds after the changes being used to supplement working capital [1] Group 2: Project Timeline Adjustments - To ensure the safe, rapid, and orderly advancement of capacity construction, the company has decided to phase the construction of the production line for the Huaian Haofan production base, extending the timeline to reach the intended use state until December 2028 [1]

Group 1 - The company achieved revenue of 270 million yuan in the first half of 2025, representing a year-on-year growth of 20.10%, and a net profit attributable to shareholders of 75.88 million yuan, up 15.31% year-on-year [1] - In Q2 2025, the company reported revenue of 135 million yuan, a year-on-year increase of 0.94%, with a net profit of 41.09 million yuan, growing 14.19% year-on-year [1] - The demand for peptide drugs, particularly GLP-1 drugs like semaglutide and tirzepatide, is rapidly increasing, contributing to the company's performance [1] Group 2 - The company has established long-term stable partnerships with over 1,900 pharmaceutical R&D and production enterprises globally, including major players like Bachem AG and Lonza AG [2] - A wholly-owned subsidiary, Highfine Biotech GmbH, was established in Germany in January 2025 to enhance connections and services for European clients [2] - The company is expanding its production capacity through self-built facilities and acquisitions, with significant projects underway to alleviate supply bottlenecks [2]